Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 547

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 5
Chunk 547
---
 $’000         %          $’000         %          $’000         %
Revenue                                                                                                    
Fruzaqla                                110,764      30.5          7,145       1.4              —         —
Elunate                                  86,333      23.7         83,181      15.7         69,950      42.7
Sulanda                                  48,972      13.5         43,935       8.3         32,304      19.7
Orpathys                                 24,507       6.7         28,866       5.5         22,260      13.6
Tazverik                            958               0.3          1,038       0.2            128       0.1
Oncology Products(1)                    271,534      74.7        164,165      31.1        124,642      76.1
R&amp;D services and licensing(2)        91,831      25.3        364,451      68.9         39,202      23.9
Total Oncology/Immunology Revenue       363,365     100.0        528,616     100.0        163,844     100.0
​

(1)   Includes Invoiced Goods—Marketed Products, Commercialization—Marketed Products and Royalties—Marketed Products. For the year ended December 31, 2024, it also includes $20 million commercial milestone under Licensing.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

(2)   Includes Research and Development—related parties, Services, Licensing and Manufacturing Supply. For the year ended December 31, 2024, $20 million commercial milestone under Licensing is excluded.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
​

Revenue from Oncology/Immunology primarily comprises revenue from Elunate, Sulanda and Orpathys in China and revenue from Fruzaqla in the United States and other ex-China markets. The revenue we generate from Elunate is primarily comprised of revenue from the sales of Elunate to Eli Lilly which we manufacture and sell at cost, promotion and marketing services to Eli Lilly and royalty revenue. The revenue we generate from Sulanda, an unpartnered drug, is primarily comprised of revenue from sales of Sulanda to distributors. The